Type 1 diabetes (T1D) is an autoimmune condition where the body cannot produce insulin properly, and this can affect the life ...

NEW YORK - Oramed Pharmaceuticals Inc . (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a market capitalization of $87 million, has announced the formation of a new joint venture, OraTech ...

A new survey has found that Type 1 diabetes can affect everyday decisions for nearly a third of those diagnosed ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

Diabetes UK estimated a further 6.3 million people are living with non-diabetic hyperglycaemia, some of whom do not know they ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Families want nurse or staff to monitor apps remotely in case of urgent alarms; schools cite shrinking budgets and internet ...

Novel approach designed to offer a more personalized and effective treatment option for patients suffering from diabetes and potentially other diseases. IRVINE, Calif., Feb. 4, 2025 /PRNewswire/ -- ...